Program
belimumab
Also written as “Belimumab”, “Belimumab 10 mg/kg” and “Belimumab 1 mg/kg”.
Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, Membranous · Arthritis, Rheumatoid · Connective Tissue Diseases · Scleroderma, Systemic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 386 open or running | phase 4since May 8, 2012 | Oct 24, 2003 | Jun 29, 2027phase 4 · NCT06411249 |
| Johnson & Johnson | 10 open or running | phase 1since Oct 29, 2020 | Oct 29, 2020 | none ahead |
Also a collaborator on its studies: icon-plc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Oct 24, 2003.
- Jan 4, 2013Phase 2 study in Glomerulonephritis, MembranousGlaxoSmithKline · NCT01762852 · United States, Australia, Canada and more
- Jul 3, 2013Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT01894360 · 81 enrolled · United States
- Apr 17, 2014Phase 3 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT02119156 · 80 enrolled · United States, China, Japan and more
- Dec 14, 2015Phase 2 study in Sjogren's SyndromeGlaxoSmithKline · NCT02631538 · 86 enrolled · Argentina, Canada, France and more
- Aug 23, 2016Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT02880852 · 20 enrolled · China
- Nov 25, 2019Phase 2 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT04179032 · 25 enrolled · United States, Argentina, Germany and more
- Oct 29, 2020Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT04611971 · 13 enrolled · Belgium
- May 26, 2021Phase 4 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT04908865 · 67 enrolled · China
- May 19, 2023Phase 3 study in Scleroderma, SystemicGlaxoSmithKline · NCT05878717 · 300 planned · United States, Argentina, Australia and more
- Jun 14, 2023Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT05917288 · 16 enrolled · China
- May 8, 2024Phase 4 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT06411249 · 302 enrolled · United States, Argentina, Brazil and more
- Aug 16, 2024Phase 3 study in Lung Diseases, InterstitialGlaxoSmithKline · NCT06572384 · 440 planned · United States, Argentina, Australia and more
- Aug 26, 2024Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT06576271 · 143 enrolled · United States, Argentina, Brazil and more
- Nov 29, 2024Phase 3 study in Connective Tissue DiseasesGlaxoSmithKline · NCT06716606 · 514 planned · United States, Argentina, Australia and more
Ahead
- Jun 29, 2027Primary completion: phase 4 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT06411249
- Feb 1, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT06576271
- Aug 30, 2029Primary completion: phase 3 study in Lung Diseases, InterstitialGlaxoSmithKline · NCT06572384
- Aug 30, 2029Primary completion: phase 3 study in Scleroderma, SystemicGlaxoSmithKline · NCT05878717
TargetBeta
“Tumor necrosis factor ligand superfamily member 13B inhibitor”ChEMBL 37, by rule
Other programs on TNFSF13B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06716606Connective Tissue Diseases · United States, Argentina, Australia and more | 3 | Recruiting | GlaxoSmithKline | Sep 27, 2030 | 514 |
| NCT06576271Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 1 | Active, not recruiting | GlaxoSmithKline | Feb 1, 2028 | 143 |
| NCT06572384Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | GlaxoSmithKline | Aug 30, 2029 | 440 |
| NCT06411249Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 4 | Active, not recruiting | GlaxoSmithKline | Jun 29, 2027 | 302 |
| NCT05917288Lupus Erythematosus, Systemic · China | 1 | Completed | GlaxoSmithKline | Oct 30, 2024 | 16 |
| NCT05878717Scleroderma, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | GlaxoSmithKline | Aug 30, 2029 | 300 |
| NCT04908865Lupus Erythematosus, Systemic · China | 4 | Completed | GlaxoSmithKline | May 23, 2024 | 67 |
| NCT04611971Healthy · Belgium | 1 | Completed | Johnson & Johnson | May 6, 2021 | 13 |
| NCT04179032Lupus Erythematosus, Systemic · United States, Argentina, Germany and more | 2 | Active, not recruiting | GlaxoSmithKline | Jan 16, 2023 | 25 |
| NCT02880852Lupus Erythematosus, Systemic · China | 1 | Completed | GlaxoSmithKline | Sep 8, 2017 | 20 |
| NCT02631538Sjogren's Syndrome · Argentina, Canada, France and more | 2 | Completed | GlaxoSmithKline | Jun 23, 2020 | 86 |
| NCT02119156Lupus Erythematosus, Systemic · United States, China, Japan and more | 3 | Completed | GlaxoSmithKline | Dec 14, 2018 | 80 |
| NCT01894360Lupus Erythematosus, Systemic · United States | 1 | Completed | GlaxoSmithKline | May 13, 2014 | 81 |
| NCT01762852Glomerulonephritis, Membranous · United States, Australia, Canada and more | 2 | Withdrawn | GlaxoSmithKline | Jan 2014 | 0 |
| NCT01705977Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 4 | Completed | GlaxoSmithKline | Jul 30, 2018 | 4,019 |
| NCT01663623Vasculitis · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | Feb 6, 2017 | 106 |
| NCT01649765Lupus Erythematosus, Systemic · United States, Argentina, Canada and more | 2 | Completed | GlaxoSmithKline | Jan 24, 2018 | 93 |
| NCT01639339Lupus Nephritis · United States, Argentina, Belgium and more | 3 | Completed | GlaxoSmithKline | Jul 25, 2019 | 448 |
| NCT01632241Lupus Erythematosus, Systemic · United States, Brazil, Colombia and more | 4 | Completed | GlaxoSmithKline | Jun 18, 2018 | 503 |
| NCT01610492Glomerulonephritis, Membranous · United Kingdom | 2 | Completed | GlaxoSmithKline | Sep 24, 2014 | 14 |
| NCT01597622Lupus Erythematosus, Systemic · Japan, Korea, Republic of | 3 | Completed | GlaxoSmithKline | Sep 13, 2018 | 142 |
| NCT01597492Lupus Erythematosus, Systemic · United States | 4 | Completed | GlaxoSmithKline | Sep 1, 2015 | 79 |
| NCT01583530Lupus Erythematosus, Systemic · United States | 1 | Completed | GlaxoSmithKline | Sep 2011 | 118 |
| NCT01536379Infections · United Kingdom | 2 | Completed | GlaxoSmithKline | Feb 2016 | 30 |
| NCT01484496Lupus Erythematosus, Systemic · United States, Argentina, Austria and more | 3 | Completed | GlaxoSmithKline | Feb 13, 2015 | 839 |
| NCT01480596Myasthaenia Gravis · United States, Canada, Germany and more | 2 | Completed | GlaxoSmithKline | Aug 2015 | 40 |
| NCT01440361Purpura | 2 | Withdrawn | GlaxoSmithKline | Apr 2015 | 0 |
| NCT01345253Lupus Erythematosus, Systemic · China, Japan, South Korea | 3 | Completed | GlaxoSmithKline | Sep 15, 2015 | 709 |
| NCT01381536Lupus Erythematosus, Systemic · Japan | 1 | Completed | GlaxoSmithKline | Nov 27, 2010 | 12 |
| NCT00732940Lupus Erythematosus, Systemic · United States, Mexico | 2 | Terminated | GlaxoSmithKline | Oct 2009 | 56 |
| NCT00724867Lupus Erythematosus, Systemic · United States | 3 | Completed | GlaxoSmithKline | Mar 2015 | 268 |
| NCT00712933Lupus Erythematosus, Systemic · Argentina, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Dec 9, 2016 | 738 |
| NCT00657007Lupus Erythematosus, Systemic · United States | 1 | Completed | GlaxoSmithKline | Mar 2003 | 70 |
| NCT00583557Arthritis, Rheumatoid · United States, Poland | 2 | Terminated | GlaxoSmithKline | Nov 2009 | 155 |
| NCT00583362Lupus Erythematosus, Systemic · United States, Canada | 2 | Completed | GlaxoSmithKline | Feb 23, 2016 | 298 |
| NCT00424476Lupus Erythematosus, Systemic · Argentina, Australia, Brazil and more | 3 | Completed | GlaxoSmithKline | May 2009 | 865 |
| NCT00410384Lupus Erythematosus, Systemic · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Sep 2009 | 819 |
| NCT00071812Arthritis, Rheumatoid · United States | 2 | Completed | GlaxoSmithKline | Jan 2005 | 283 |
| NCT00071487Lupus Erythematosus, Systemic · United States, Canada | 2 | Completed | GlaxoSmithKline | Aug 2005 | 449 |
How it is read
Names in the registry
- “Belimumab”, 16 entries
- “Belimumab 10 mg/kg”, 7 entries
- “belimumab”, 7 entries
- “Belimumab 1 mg/kg”, 5 entries
- “Belimumab 10 mg/kg plus standard therapy”, 3 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 25 studies
- Glomerulonephritis, Membranous, 2 studies
- Arthritis, Rheumatoid, 2 studies
- Connective Tissue Diseases, 1 study
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.